Pcn346 - Disease Specific Cost Analysis of the Nonmetastatic Castration-Resistant Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer Health States

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.428
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Yearbook of Paediatric Endocrinology
2019English

Prostate-Specific Membrane Antigen–Directed Therapy for Metastatic Castration-Resistant Prostate Cancer

Cancer Journal
Cancer ResearchOncology
2016English

Visceral Disease in Castration-Resistant Prostate Cancer

European Urology
Urology
2014English

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Clinical Medicine Insights: Oncology
Oncology
2013English

Patient Reported Outcomes in Metastatic Castration-Resistant Prostate Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Metastatic Castration-Resistant Prostate Cancer: The Emerging Continuum of Care

Journal of the Canadian Urological Association
OncologyUrology
2013English

Aggressive Variants of Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer Through AHNAK

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2019English

Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy